How does antifungal pharmacology differ for mucormycosis versus aspergillosis?

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 1, 2012, Pages

  Lewis, Russell E ^a,e   Lortholary, Olivier ^b   Spellberg, Brad ^c   Roilides, Emmanuel ^d   Kontoyiannis, Dimitrios P ^e   Walsh, Thomas J ^f  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UCLA MEDICAL CENTER   (United States)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CYCLOSPORIN; ERGOSTEROL; ITRACONAZOLE; MICAFUNGIN; NIKKOMYCIN Z; POLYENE; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CELL MEMBRANE; CELL WALL; CUNNINGHAMELLA; DRUG POTENTIATION; DRUG TARGETING; FUNGAL GENE; FUNGAL STRAIN; GENE SEQUENCE; GENOME; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MUCOR; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS ORYZAE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CELL MEMBRANE; CELL WALL; DRUG RESISTANCE, MULTIPLE, FUNGAL; ERGOSTEROL; GENE DUPLICATION; GENOME, FUNGAL; GENOMIC INSTABILITY; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MUCORMYCOSIS; PYRIMIDINES; RHIZOPUS; SPECIES SPECIFICITY; TRIAZOLES; VIRULENCE FACTORS;

EID: 84855864796     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir884     Document Type: Article

References (58)

1. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica 2010;95:644-50.
2. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48:265-73.
3. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-40. (Pubitemid 46233255)
4. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009;15:1395-401.
5. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011;17:1855-64.
6. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53. (Pubitemid 41170352)
7. Ma LJ, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009;5:e1000549.
8. Schoen C, Reichard U, Monod M, Kratzin HD, Ruchel R. Molecular cloning of an extracellular aspartic proteinase from Rhizopus microsporus and evidence for its expression during infection. Med Mycol 2002;40:61-71. (Pubitemid 34168309)
9. Spreer A, Ruchel R, Reichard U. Characterization of an extracellular subtilisin protease of Rhizopus microsporus and evidence for its expression during invasive rhinoorbital mycosis. Med Mycol 2006;44:723-31. (Pubitemid 44824450)
10. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982;31:1109-14. (Pubitemid 13242245)
11. Artis WM, Patrusky E, Rastinejad F, Duncan RL Jr. Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: alternative to simple iron deprivation. Infect Immun 1983;41:1269-78. (Pubitemid 13048606)
12. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-5.
13. Coste A, Selmecki A, Forche A, et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 2007;6:1889-904. (Pubitemid 47585577)
14. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 2008;68:624-41. (Pubitemid 351490182)
15. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15. (Pubitemid 43807519)
16. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2. (Pubitemid 34415351)
17. Dannaoui E, Meletiadis J, Mouton JW, Meis J, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003;51:45-52. (Pubitemid 36163826)
18. Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008;52:1573-6. (Pubitemid 351522040)
19. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiarycare cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60.
20. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009;200:1002-11.
21. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:24-34.
22. Lamaris GA, Ben-Ami R, Lewis RE, Kontoyiannis DP. Does preexposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. J Antimicrob Chemother 2008;62:539-42.
23. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediat Inf Dis J 1999;18:702-8. (Pubitemid 29382466)
24. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503-9.
25. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-97. (Pubitemid 46717290)
26. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007;51:1253-8. (Pubitemid 46586802)
27. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010;54:1298-304.
28. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008;52:3637-41.
29. Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006;50:3418-23. (Pubitemid 44527518)
30. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000;182:274-82. (Pubitemid 30497814)
31. Walsh TJ, Jackson AJ, Lee JW, et al. Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits. Antimicrob Agents Chemother 2000;44:2068-76. (Pubitemid 30484428)
32. Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998;42:2391-8. (Pubitemid 28420384)
33. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-96. (Pubitemid 33107867)
34. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005;49:830-2. (Pubitemid 40175710)
35. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47:364-71. (Pubitemid 352009357)
36. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006;50:3968-9. (Pubitemid 44684931)
37. Spellberg B, Andes D, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009;53:3122-5.
38. Davis LL, Bartnicki-Garcia S. The co-ordination of chitosan and chitin synthesis in Mucor rouxii. J Gen Microbiol 1984;130:2095-102. (Pubitemid 14053888)
39. Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1, 3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005;49:721-7. (Pubitemid 40175685)
40. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008;52:1556-8. (Pubitemid 351522035)
41. Lewis RE, Leventakos K, Liao G, Kontoyiannis DP. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Ch 2011;55:3584-7.
42. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 2008;4:e1000040.
43. Fortwendel JR, Juvvadi PR, Perfect BZ, Rogg LE, Perfect JR, Steinbach WJ. Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob Agents Chemother 2010;54:1555-63.
44. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008;47:226-35. (Pubitemid 351952889)
45. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated betaglucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008;198:186-92. (Pubitemid 352019283)
46. Werner JL, Metz AE, Horn D, et al. Requisite role for the dectin-1 betaglucan receptor in pulmonary defense against Aspergillus fumigatus. J Immunol 2009;182:4938-46.
47. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47. (Pubitemid 27020567)
48. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9. (Pubitemid 46147619)
49. Shibuya K, Ando T, Hasegawa C, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother 2004;10:138-45. (Pubitemid 39044966)
50. Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine andmethylprednisoloneinduced immunosuppression. Am J Respir Crit Care Med 1995;152:1079-86.
51. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect 2009;59:134-8.
52. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007;45:e101-4. (Pubitemid 47580399)
53. Saoulidis S, Simitsopoulou M, Dalakiouridou M, et al. Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model. Mycoses 2011;54:e486-92.
54. Spellberg B, Walsh TJ, Kontoyiannis DP, John Edwards Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009;48:1743-51.
55. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993;6:1-21. (Pubitemid 23055191)
56. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001;45:3310-21. (Pubitemid 33107840)
57. Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother 2009;53:3549-51.
58. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and fromferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994;47:1843-50. (Pubitemid 24172854)